1. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial;Yao;J Clin Oncol,2010
2. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT [ASCO Meeting Abstracts];Chawla;J Clin Oncol,2011
3. Febrile neutropenia;Patel;JAMA Oncol,2017
4. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia;Serefhanoglu;Ann Acad Med Singapore,2006
5. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006